TY - JOUR
T1 - V-Set Immunoglobulin Domain–Containing Protein 4 as a Novel Serum Biomarker of Lupus Nephritis and Renal Pathology Activity
AU - Tang, Chenling
AU - Zhang, Shu
AU - Teymur, Aygun
AU - Yang, Bowen
AU - Nazir, Fariz
AU - Cai, Qi
AU - Saxena, Ramesh
AU - Olsen, Nancy J.
AU - Mohan, Chandra
AU - Wu, Tianfu
N1 - Publisher Copyright:
© 2023 American College of Rheumatology.
PY - 2023/9
Y1 - 2023/9
N2 - Objective: To discover novel serum biomarkers that have diagnostic or predictive value in lupus nephritis (LN). Methods: Using a quantitative protein microarray, we screened for high-abundant proteome expression in the serum of patients with LN compared to healthy controls. Top candidates from this screening were validated using a larger cohort of patients with LN compared to a disease control cohort (subjects with other chronic kidney diseases) and a healthy control cohort. Promising markers were then selected using a machine-learning model and further validated with a larger patient cohort. The corresponding autoantibodies and immune complexes containing these proteins were also examined. Results: In total, 13 proteins were found to be significantly elevated in LN patient serum in the screening, among which 8 proteins were validated by enzyme-linked immunosorbent assay using 81 serum samples from LN patients and control subjects. Three serum markers with LN diagnostic potential were identified using feature importance analysis and further validated using 155 serum samples from LN patients and control subjects. V-set immunoglobulin domain–containing protein 4 (VSIG4) appeared to be the most promising marker in distinguishing LN from healthy controls, with an area under the curve of 0.93. VSIG4 could also discriminate active LN from inactive LN. Furthermore, serum VSIG4 levels were positively correlated with all of the following clinical parameters: the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (Spearman's rank correlation rs = 0.42, P < 0.001), the renal domain score of the SLEDAI (rs = 0.46, P < 0.001), the urinary protein-to-creatinine ratio (rs = 0.56, P < 0.001), and the serum creatinine level (rs = 0.41, P < 0.001). Importantly, we found that serum VSIG4 levels tracked with LN disease activity longitudinally, and that serum VSIG4 levels reflected the renal pathology activity index (AI), particularly the AI components of crescent formation and hyaline deposits. Conclusion: VSIG4 may be a promising novel serum biomarker and therapeutic target in patients with LN. (Figure presented.).
AB - Objective: To discover novel serum biomarkers that have diagnostic or predictive value in lupus nephritis (LN). Methods: Using a quantitative protein microarray, we screened for high-abundant proteome expression in the serum of patients with LN compared to healthy controls. Top candidates from this screening were validated using a larger cohort of patients with LN compared to a disease control cohort (subjects with other chronic kidney diseases) and a healthy control cohort. Promising markers were then selected using a machine-learning model and further validated with a larger patient cohort. The corresponding autoantibodies and immune complexes containing these proteins were also examined. Results: In total, 13 proteins were found to be significantly elevated in LN patient serum in the screening, among which 8 proteins were validated by enzyme-linked immunosorbent assay using 81 serum samples from LN patients and control subjects. Three serum markers with LN diagnostic potential were identified using feature importance analysis and further validated using 155 serum samples from LN patients and control subjects. V-set immunoglobulin domain–containing protein 4 (VSIG4) appeared to be the most promising marker in distinguishing LN from healthy controls, with an area under the curve of 0.93. VSIG4 could also discriminate active LN from inactive LN. Furthermore, serum VSIG4 levels were positively correlated with all of the following clinical parameters: the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (Spearman's rank correlation rs = 0.42, P < 0.001), the renal domain score of the SLEDAI (rs = 0.46, P < 0.001), the urinary protein-to-creatinine ratio (rs = 0.56, P < 0.001), and the serum creatinine level (rs = 0.41, P < 0.001). Importantly, we found that serum VSIG4 levels tracked with LN disease activity longitudinally, and that serum VSIG4 levels reflected the renal pathology activity index (AI), particularly the AI components of crescent formation and hyaline deposits. Conclusion: VSIG4 may be a promising novel serum biomarker and therapeutic target in patients with LN. (Figure presented.).
UR - http://www.scopus.com/inward/record.url?scp=85164304757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164304757&partnerID=8YFLogxK
U2 - 10.1002/art.42545
DO - 10.1002/art.42545
M3 - Article
C2 - 37163449
AN - SCOPUS:85164304757
SN - 2326-5191
VL - 75
SP - 1573
EP - 1585
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 9
ER -